# KPL-301 for Subjects With Giant Cell Arteritis

> **NCT03827018** · PHASE2 · COMPLETED · sponsor: **Kiniksa Pharmaceuticals, Ltd.** · enrollment: 70 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **COMBINATION_PRODUCT:** mavrilimumab
- **COMBINATION_PRODUCT:** placebo
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT03827018
- **Lead sponsor:** Kiniksa Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-20
- **Primary completion:** 2020-08-13
- **Final completion:** 2020-11-25
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03827018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03827018, "KPL-301 for Subjects With Giant Cell Arteritis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03827018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*